The Latest

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    5 drug startups have raised more than $1.4 billion combined this week, continuing an upturn in venture funding that began in September.

    Updated Oct. 15, 2025
  • APP_20mm Seal-Stopper_Vial Size 10_Valor-V2
    Image attribution tooltip
    Permission granted by West Pharmaceutical Services
    Image attribution tooltip
    Sponsored by West Pharmaceutical Services

    Pioneering perspectives: 4 core principles in drug packaging

    Start smart: Early packaging decisions can make or break your drug's market launch. Choose the best packaging and secure the future.

  • White flags bearing Novo Nordisk's logo are seen against a blue sky.
    Image attribution tooltip
    Courtesy of Novo Nordisk
    Image attribution tooltip

    Novo wagers up to $2.1B on Omeros’ rare disease drug

    The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called complement-mediated diseases.

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly, battling skepticism, reinforces GLP-1 pill’s case with new study data

    Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more late-stage trials. 

  • Hospital Hallway with Doctors, Nurses and Specialists in Hospital. F
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    California passes laws targeting PBMs, private equity

    Gov. Gavin Newsom signed an array of healthcare bills into law last week that crack down on pharmacy benefit managers and beef up the review process for deals involving private equity firms.

  • A 3D visualization of antibody drug conjugates.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Cancer drug startup Tubulis raises $361 million for ADCs

    The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer drug that’s being showcased at a medical meeting on Sunday.

  • An illustration of glucose-dependent insulinotropic peptide.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Kailera nets $600M more to advance Zepbound-like obesity drug

    Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that just succeeded in late-stage testing in China.

  • An infant's left ear is in the foreground of this image, which is otherwise blurred.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy

    Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a dozen children with a rare, genetic form of deafness.

  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    BioCryst goes ‘all in’ on rare swelling disease with Astria deal

    A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema that complements its daily pill.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance

    AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, Novo is shuttering its cell therapy division and an investor wants Novavax to sell itself.

  • Left: Todd Zavodnick, CEO of Excellergy; right: Geoff Harris, chief scientific officer of Excellergy.
    Image attribution tooltip
    Permission granted by Excellergy
    Image attribution tooltip
    Startup launches

    A young biotech nets $70M for a new type of allergy drug

    Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company says could lead to faster and more complete disease control.

  • A wall bearing the Johnson & Johnson logo is seen outside of an office building.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    J&J plans to spin out orthopedics business

    CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such as cardiovascular and robotics.

  • An illustration of B cells producing antibodies
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Bristol’s $1.5B Orbital buyout extends ‘in vivo’ cell therapy deal streak

    The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically modify immune cells inside the body. 

  • The HHS in DC
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Trump administration moves to fire HHS employees amid shutdown

    “HHS employees across multiple divisions have received reduction-in-force notices,” an administration spokesperson confirmed. It’s a significant escalation of normal shutdown procedures.

    FDA
  • A micrograph showing triglyceride fat accumulated inside liver cells.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novo joins MASH dealmaking surge with $4.7B Akero buyout

    The deal is the third acquisition since May involving a drug that could reverse liver scarring in people with metabolic dysfunction-associated steatohepatitis. 

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech’s M&A outlook is uncertain. Track the deals that are happening here.

    BioCryst is acquiring Astria Therapeutics in a cash-and-stock deal that gives the company a long-acting preventive therapy for the rare disease hereditary angioedema.

    Updated Oct. 14, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    AstraZeneca ups investment in Virginia; Moderna vets launch VC fund

    The British pharma is adding $500 million, and ADC production capabilities, to a planned Virginia facility. Elsewhere, Ferring announced layoffs and Sanofi touted a radiopharmaceutical drug.

  • A sign spelling Nasdaq hangs on the side of a building while a pedestrian passes by.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Evommune files for IPO to advance immune drug work

    The company believes its lead drug, which is currently in mid-stage testing, could address limitations of other therapies for chronic skin hives.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Evommune on Thursday outlined plans for an offering that would support development of two drugs in mid-stage testing for urticarias and atopic dermatitis.

    Updated Oct. 9, 2025
  • A Regeneron sign in front of a building.
    Image attribution tooltip
    Courtesy of Regeneron Pharmaceuticals
    Image attribution tooltip

    Regeneron, needing a turnaround, gains new use for cancer drug

    Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the “broad-reaching implications” for Regeneron's Eylea franchise investors had hoped.

  • A bottle of pills lays on top of a sheet of $100 bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Venture firms pour $101M into a biotech using the brain to fix the immune system

    Nilo Therapeutics, which launched Wednesday, is trying to develop drugs that regulate inflammation and the immune system by targeting a special kind of nerve cell.

  • This is a pseudo-colored image of high-resolution gradient-echo MRI scan of a fixed cerebral hemisphere from a person with multiple sclerosis.
    Image attribution tooltip
    Bhagavatheeshwaran, Govind. (2016). "MRI Scan" [Image]. Retrieved from Flickr.
    Image attribution tooltip
    China competition

    Zenas looks to China to stock pipeline with 3 more immune drugs

    A potentially $2 billion deal with InnoCare Pharma hands Zenas rights to a BTK inhibitor in late-stage testing for multiple sclerosis and two other immune medicines in earlier development.

  • A person sits at a table and pours pills into there hand.
    Image attribution tooltip
    Permission granted by Michael Sage
    Image attribution tooltip
    Deep Dive // Pain drugs

    Cancer patients are living longer than ever. Pain drugmakers haven’t kept up.

    Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily pain. Doctors fear that’s bound to continue.

  • single science glass flask with double exposure scientist holding tube in chemistry blue laboratory with stock market information background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Arthrosi snags $153M in pursuit of a new gout drug

    The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve upon existing therapies. 

  • A photo of FDA CBER Director Peter Marks delivering remarks at a public workshop on March 3, 2020.
    Image attribution tooltip
    Ermath, Michael. (2020). "Individualized Therapies Workshop" [Photograph]. Retrieved from Flickr.
    Image attribution tooltip

    Peter Marks, former top FDA vaccine official, joins Eli Lilly

    Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work at the big Indianapolis drugmaker.

  • A 3D illustration of human lungs.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Boehringer Ingelheim drug wins FDA OK in tough-to-treat lung disease

    The clearance makes Jascayd the first new drug for idiopathic pulmonary fibrosis in over a decade, but some analysts see it as a “modest” advance in care.